Spravato Treatment in Lathrop, CA
Amrit Mind & Body Psychiatry offers Spravato treatment for adults living with treatment resistant depression. We guide every patient through eligibility screening, in office administration, and ongoing monitoring, so you receive this treatment safely and with a provider who tracks your progress at every step.
If standard antidepressants have not worked for you, Spravato treatment may offer a faster path to relief. Our board certified psychiatric team evaluates your history, confirms eligibility, and builds a treatment plan designed around your specific diagnosis and goals.
Individual Counseling
Find clarity and strength to manage stress, anxiety, depression, or any personal challenges.
Family Counseling
Family life can be complicated. We provide guidance to improve communication.
Assessments & Testing
Professional assessments give insight into emotional, behavioral, and cognitive patterns.
Online Counseling
No matter where you are, you can access support through secure, convenient online sessions.
What Is Spravato Treatment?
Spravato (esketamine) is an FDA approved nasal spray medication that treats adults with treatment resistant depression, defined as depression that has not responded adequately to at least two oral antidepressants. Unlike traditional antidepressants, Spravato acts on the brain’s glutamate system rather than serotonin pathways, which allows it to work faster for many patients.
As of January 2025, the FDA approved Spravato as a standalone monotherapy, meaning eligible patients can now receive Spravato treatment without also taking a daily oral antidepressant. This expanded approval gives our providers more flexibility to personalize your treatment plan, especially if you have struggled with side effects from oral antidepressants in the past.
How Spravato Treatment Works
We administer Spravato treatment in our Lathrop office under direct clinical supervision, in line with the FDA’s REMS safety program. Here is what the process typically looks like:
Evaluation and Screening
We review your depression diagnosis, prior treatment history, and current health to confirm you meet the clinical criteria for treatment resistant depression.
Induction Phase
You self administer the nasal spray in our office, typically twice a week for the first four weeks, while our team monitors your response and adjusts your dose as needed.
Taper and Maintenance
As your symptoms improve, sessions space out to once a week, then to once every one to two weeks for ongoing maintenance, based on how you respond to treatment.
Monitoring
Spravato can cause temporary sedation or dissociation, you remain in our office for a required observation period after each dose, and you cannot drive yourself home the same day.
Clinical trial data supporting the monotherapy approval showed meaningful improvement in depression symptoms within 24 hours of the first dose for many patients, with continued improvement through the following weeks.
Who Qualifies for Spravato Treatment
Spravato treatment is appropriate for adults who meet the clinical definition of treatment resistant depression, meaning an inadequate response to at least two different oral antidepressants tried at adequate dose and duration. During your evaluation, we also screen for conditions that may affect eligibility, and we discuss whether Spravato works better for you as a standalone treatment or alongside an oral antidepressant.
This treatment is not appropriate for everyone, and our team will walk you through the full risks, benefits, and alternatives during your consultation.
Spravato vs Ketamine Therapy
Patients often ask how Spravato treatment compares to ketamine therapy. Spravato contains esketamine, is FDA approved specifically for treatment resistant depression, and is administered as a nasal spray under a structured REMS program. Ketamine therapy uses a different formulation and is typically administered by other routes. Both target the same glutamate pathway in the brain, but they differ in approval status, administration, and how insurance covers them. We help you understand which option fits your diagnosis and treatment history during your evaluation.
This treatment is not appropriate for everyone, and our team will walk you through the full risks, benefits, and alternatives during your consultation.
Why Choose Amrit Mind & Body Psychiatry for Spravato Treatment
Our providers are board certified and bring direct clinical experience delivering Spravato treatment to patients with treatment resistant depression.
We prioritize continuity of care, so the same team that screens you for eligibility also administers your treatment and monitors your progress over time, rather than passing you between different providers at each visit.
If oral antidepressants have not given you the relief you need, Spravato treatment may be the next step. Schedule a consultation with our board certified psychiatric team in Lathrop, CA, and find out if you qualify.
This treatment is not appropriate for everyone, and our team will walk you through the full risks, benefits, and alternatives during your consultation.
FAQ's
Am I a candidate for Spravato treatment?
You may be a candidate if you have major depressive disorder and have not responded adequately to at least two oral antidepressants. We confirm eligibility during a full clinical evaluation.
Do I still need to take an oral antidepressant with Spravato?
Not necessarily. Since January 2025, the FDA approved Spravato as a monotherapy, so eligible patients can receive Spravato treatment on its own. Some patients still benefit from combining it with an oral antidepressant, which we determine based on your history.
How quickly does Spravato treatment work?
Clinical trial data shows some patients experience improvement in depressive symptoms within 24 hours of the first dose, with continued improvement over the following weeks. Individual results vary.
Does insurance cover Spravato treatment?
Many insurance plans cover Spravato treatment for patients who meet the clinical criteria for treatment resistant depression. Contact our office and we will help verify your specific benefits before you begin treatment.
Is Spravato treatment safe?
Spravato treatment carries risks, including temporary sedation, dissociation, and increased blood pressure, which is why it is administered only under direct clinical supervision through the FDA’s REMS program. We review your full risk profile before starting treatment.
